trending Market Intelligence /marketintelligence/en/news-insights/trending/aw962yveq6jt3a5nkqqiwg2 content esgSubNav
In This List

Dawnrays Pharmaceutical executive director resigns

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Dawnrays Pharmaceutical executive director resigns

Hong Kong-based Dawnrays Pharmaceutical (Holdings) Ltd. said Li Tung Ming has resigned as an executive director of the company.

Ming also resigned as a board member of Suzhou Dawnrays Pharmaceutical Co. Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co. Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co. Ltd. and Guangdong Dawnrays Pharmaceutical Co. Ltd., which are subsidiaries of Dawnrays.

Ming, who resigned due to health reasons, will remain with the company in an advisory role.

Dawnrays Pharmaceutical is an investment holding company that develops, manufactures, and sells nonpatented pharmaceutical medicines in mainland China and internationally.